|Bid||72.50 x 800|
|Ask||80.00 x 800|
|Day's Range||74.64 - 76.74|
|52 Week Range||44.58 - 109.00|
|Beta (3Y Monthly)||1.45|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 19, 2019 - Feb 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||100.14|
Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Blueprint Medicines Corp NASDAQ/NGS:BPMCView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for BPMC with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding BPMC totaled $2.45 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
CAMBRIDGE, Mass. , Feb. 7, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, ...
HOUSTON, TX / ACCESSWIRE / January 24, 2019 / Healthcare is quickly being disrupted by artificial intelligence. In fact, AI is quickly proving it can spot warning signs of disease before we're even aware of it ourselves. "Artificial intelligence could also use the way we look to help us predict future disease.
Pharma giant Eli Lilly put together its winning bid for Loxo Oncology in just 10 days ahead of the J.P. Morgan Healthcare Conference, according to documents filed Thursday with the SEC.
Shares of all three cancer-focused companies shot higher after one of their peers got bought out for a sizable premium.
The third multibillion-dollar buyout of cancer-treatment developers in the past month was a charm for the shares of targeted oncology companies, as Leerink analyst Andrew Berens said Eli Lilly’s deal to buy Loxo Oncology validated the “significant value and interest” in the sector.
-- Top-line avapritinib data support planned NDA for PDGFRA Exon 18 mutant GIST and fourth-line GIST in first half 2019 -- -- Registration-enabling trials for avapritinib in advanced and indolent systemic ...
NEW YORK, Dec. 17, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying for a while now that the current market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the fourth quarter, […]
In 2014 Jeff Albers was appointed CEO of Blueprint Medicines Corporation (NASDAQ:BPMC). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then we’ll Read More...
- 83% overall response rate, with evidence of deepening of response over time - - Median duration of response not reached; 12-month duration of response rate of 76% - - Statistically significant improvements ...
- 84% ORR in PDGFRα D842V GIST and 20% ORR in fourth-line or later GIST support plans to submit New Drug Application to FDA in the first half of 2019 - - 26% ORR in regorafenib-naïve third- and fourth-line ...
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -5.73% and -45.79%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Cambridge, Massachusetts-based company said it had a loss of $1.66 per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
- Avapritinib receives Breakthrough Therapy Designation for treatment of advanced SM - - First patient screened in registration-enabling PATHFINDER trial in advanced SM - - Received FDA feedback supporting ...
CAMBRIDGE, Mass., Oct. 29, 2018 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced the appointment of Christina Rossi as Chief Commercial Officer, effective October 29, 2018. Blueprint Medicines also announced the appointment of Paul Beresford as General Manager, International. In her new role, Ms. Rossi will join the executive management team and have overall responsibility for commercial strategy and operations, including sales and marketing, for a potential commercial launch of avapritinib in the United States in 2019 and pre-commercial planning across Blueprint Medicines' pipeline.